Atazanavir + Didanosine (enteric-coated) + Efavirenz + Emtricitabine + Emtricitabine/Tenofovir disoproxil fumarate + Lamivudine/Zidovudine

ApprovedCompleted
0 watching 0 views this week๐Ÿ”ฅ Hot
80
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
โœ“
Phase 3
5
Approved
Indication / Disease

HIV Infections

Conditions

HIV Infections

Trial Timeline

May 1, 2005 โ†’ May 1, 2010

About Atazanavir + Didanosine (enteric-coated) + Efavirenz + Emtricitabine + Emtricitabine/Tenofovir disoproxil fumarate + Lamivudine/Zidovudine

Atazanavir + Didanosine (enteric-coated) + Efavirenz + Emtricitabine + Emtricitabine/Tenofovir disoproxil fumarate + Lamivudine/Zidovudine is a approved stage product being developed by Allergy Therapeutics for HIV Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT00084136. Target conditions include HIV Infections.

Hype Score Breakdown

Clinical
30
Activity
20
Company
5
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT00084136ApprovedCompleted